Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;1(3):317-22.

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%

Ronald L Gross  1 , E Kenneth Sullivan, David T Wells, Sushanta Mallick, Theresa A Landry, Michael V W Bergamini
Affiliations
Free PMC article

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%

Ronald L Gross et al. Clin Ophthalmol. 2007 Sep.
Free PMC article

Abstract

Purpose: To compare the IOP-lowering efficacy of the fixed combination of travoprost 0.004%/timolol 0.5% dosed once daily in the morning with the concomitant administration of travoprost 0.004% dosed once daily in the evening and timolol 0.5% dosed once daily in the morning.

Methods: This was an analysis of pooled data from two similarly designed prospective, randomized, controlled clinical trials comparing the fixed combination and concomitant therapy.

Results: Mean IOP ranged from 15.7 to 16.8 mmHg for the fixed combination group, and from 15.1 to 16.4 mmHg for the concomitant group. Mean IOP reductions were up to 9.0 mmHg in the fixed combination group, and up to 8.8 mmHg in the concomitant group. The differences in mean IOP change between treatment groups ranged from -0.2 to +0.9 mmHg across visits and time points. The safety profile was generally similar between groups. An exception was the incidence of ocular hyperemia, which was 13.7% with the fixed combination and 20.8% with concomitant therapy (p = 0.02).

Conclusion: The fixed combination of travoprost 0.004% and timolol 0.5% provides IOP-lowering efficacy that is similar to concomitant administration of travoprost 0.004% dosed once daily in the evening and timolol 0.5% dosed once daily in the morning.

Keywords: glaucoma; ocular hypertension; prostaglandin; timolol; travoprost.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of mean IOP for travoprost 0.004%/timolol 0.5% fixed combinaiton and concomitant travoprost 0.004% and timolol 0.5%.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian latanoprost study group. Ophthalmology. 1995;102:1743–52. - PubMed
    1. Baun O, Heegaard S, Kessing SV, et al. The morphology of conjunctiva after long-term topical anti-glaucoma treatment. A quantitative analysis. Acta Ophthalmol Scand. 1995;73:242–5. - PubMed
    1. Broadway DC, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994a;112:1437–45. - PubMed
    1. Broadway DC, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994b;112:1446–54. - PubMed
    1. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132–5. - PubMed

LinkOut - more resources